Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

47.04 +0.84 (+1.82%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
40 41 Next >
News headline image
AIRC Stock Alert: Blackstone Is Taking Apartment Income REIT Private ↗
Apartment Income REIT stock is rising higher on Monday as investors in AIRC shares react to a deal to take the company private. 
Via InvestorPlace
News headline image
Sanofi Layoffs 2024: What to Know About the Latest SNY Job Cuts ↗
Sanofi layoffs are coming for the company's R&D employees and it makes major changes to how it handles development going forward. 
Via InvestorPlace
Topics Workforce
News headline image
In Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster ↗
Sanofi reaches a settlement in principle for about 4,000 Zantac lawsuits in the US, excluding Delaware, regarding alleged cancer risks linked to NDMA. Financial terms remain undisclosed. 
Via Benzinga
Topics Lawsuit
News headline image
What's Going On European Pharma Giant AstraZeneca Stock On Wednesday? ↗
Japan approves AstraZeneca & Sanofi's Beyfortus for respiratory syncytial virus in neonates, infants, & children. Also, Truqap receives approval for unresectable or recurrent breast cancer. AstraZeneca... 
Via Benzinga
News headline image
How Is The Market Feeling About Sanofi? ↗
 
Via Benzinga
News headline image
(SNY) - Analyzing Sanofi's Short Interest ↗
 
Via Benzinga
News headline image
Why the dividend investor may take a look at NASDAQ:SNY. ↗
Exploring SANOFI-ADR (NASDAQ:SNY)'s dividend characteristics. 
Via Chartmill
News headline image
NASDAQ:SNY is an undervalued gem with solid fundamentals. ↗
SANOFI-ADR (NASDAQ:SNY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
News headline image
Krispy Kreme-McDonald's Deal Spikes Insulin Stock Interest: 'We're About To Cash In On The Aftermath' ↗
Krispy Kreme's partnership with McDonald's has led to a surge in stock prices. Investors are turning to insulin stocks to capitalize on the growing demand. 
Via Benzinga
News headline image
To the Moon and Beyond: 7 Stocks With Cosmic Potential ↗
With the Fear and Greed Index at 69, it's an opportune to wager on these attractive Stocks with Moonshot Potential. 
Via InvestorPlace
News headline image
Passport to Profits: 7 Global Growth Gems to Diversify Your Holdings ↗
With certain sectors in the domestic market appearing overstretched, these global growth stocks may offer better opportunities. 
Via InvestorPlace
News headline image
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits ↗
Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising. 
Via InvestorPlace
News headline image
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields ↗
A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year. 
Via Benzinga
News headline image
3 Cash Cow Dividend Stocks for Outsized Income & Upside ↗
With uncertainty again weighing on the market, investors can take shelter under these cash cow dividend stocks. 
Via InvestorPlace
News headline image
6 reasons to buy Teva Pharmaceuticals stock sooner than later
Investors seeking a long-term and undervalued pharmaceutical play should take a close look at Teva Pharmaceuticals, and here are six reasons why 
Via MarketBeat
Topics Lawsuit
News headline image
Move Over Magnificent 7, Say Hello to the GRANOLAS ↗
Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods. 
Via InvestorPlace
News headline image
Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests ↗
The FDA put studies in eczema and asthma treatment on clinical hold. 
Via Investor's Business Daily
News headline image
Cruising For A Bruising ↗
We’re currently living in the soft landing, and it is pleasant indeed. But inflation numbers at the start of the year have put us on notice. Like the Magnificent Seven, hopes of a sustained soft... 
Via Talk Markets
Topics Economy
News headline image
2 Healthcare Stocks You Can Buy and Hold for the Next Decade ↗
Don't count these companies out too soon. 
Via The Motley Fool
News headline image
7 Contrarian Biotech Stocks to Consider Amid Sector Weakness ↗
Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts. 
Via InvestorPlace
News headline image
The 3 Biotech Stocks That Could Make Your February Unforgettable ↗
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks. 
Via InvestorPlace
News headline image
What's Going On Eli Lilly Stock Thursday? ↗
Eli Lilly's impressive stock surge, better-than-expected Q4 results, and positive analyst reviews. 
Via Benzinga
News headline image
Novo Nordisk To Up Production Capacity As Parent Buys Catalent ↗
NVO stock rose after Novo Nordisk's parent, Novo Holdings, said it has agreed to buy contract manufacturer Catalent for $11.5 billion in cash. 
Via Investor's Business Daily
News headline image
CytoReason's AI-Driven Disease Model Platform Trusted By 5 Top 10 Pharma Companies Harnesses Big Data To Speed Drug Discovery And Development ↗
Click here to learn more about CytoReason and how to invest through OurCrowd.  
Via Benzinga
News headline image
Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets ↗
Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones. 
Via Talk Markets
News headline image
Why Is Sanofi Partner Regeneron Pharmaceuticals Stock Trading Higher Today? ↗
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $11.86, down 6% Y/Y, beating the consensus of $10.77. 
Via Benzinga
News headline image
Sanofi (SNY) Q4 2023 Earnings Call Transcript ↗
SNY earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results. 
Via Benzinga
News headline image
French Pharma Giant Sanofi's Q4 Earnings Hit By Aubagio Generic Competition, Helped By Flagship Eczema And Newly Launched Hemophilia Drugs ↗
Sanofi reports Q4 operating income of €2.6B, down 5.2%. Revenues rise 1.8% to €10.92B, Specialty Care grows 13.7%, Dupixent sales surge. 
Via Benzinga
News headline image
Sanofi's Biggest Drug Shined. But The Rest Of Its Business Didn't. ↗
The company missed total sales and earnings expectations. 
Via Investor's Business Daily
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.